The Ventures branch of Channel 4, the state diffuser, takes a participation in a new digital health business which aims to help fight against the growing scourge of chronic allergies in the United Kingdom.
Sky News has learned that Allergyrhino, who has been set up to provide patients with access to personalized allergic immunotherapy, concluded an agreement with Channel 4 Ventures as part of a fundraising that also includes the investment company at the start of the Lexham Partners stadium.
The so -called media arrangement for equity will give the Allergyrhino brand using Channel 4’s advertising inventory because it seeks to create name recognition.
This is the last agreement of this type signed by Channel 4 Ventures, with previous counterparts that included the online real estate agent Purplebricks and Crowdcube, the crowd financing platform.
Money Dernited: Tax warning on state pension
Allergyrhino is chaired by Dr. Sneh Khemka, a former world medical chief of Bupa and former director of the head of Simplyhealth.
This counts Professor Adam Fox, former president of the British Society for Allergy and Clinical Immunology, and Professor Stephen Till, consultant allergist at Guy’s and St Thomas’ NHS Foundation Trust, among the members of his clinical advisory team.
The training of the company occurs as the problem of chronic allergies soar in Great Britain, with data suggesting that one in four people now live with seasonal or persistent rhinitis, triggered by factors such as hay fever and dust allergies.
It is said that it would be the chronic condition for the fastest growth in children.
Its financing round – encompassing the value of the agreement and capital of Channel 4 ventures of Lexham – was worth more than 4 million pounds sterling.
Channel 4 refused to comment, while neither the Rhino nor Lexham allergy could be joined to comment.